FY2023 · ended Dec 31, 2023 · Revenue $37,653, -71.4% YoY · Filed Mar 14, 2025
Oragenics, Inc. (OGEN) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$37,653
-71.4% vs prior year
Net income
$-9.84M
+6.9% vs prior year
Operating cash flow (TTM)
$-10.21M
-37.7% vs year-ago TTM
Free cash flow
$-15.36M
-13.6% vs prior year
EPS
$-4.56
+90.5% vs prior year
Dividend per share
None
Shares outstanding
4.34M
-79.8% vs prior year
Net cash
$3.47M
FY 2023
Operating margin
-55519.9%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OGEN (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Lakewood Ranch, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1174940
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $37,653 | $131,521 | $86,987 |
| Operating income | -$9.4M | -$10.6M | -$20.9M | -$14.4M | -$15.8M |
| Net income | -$9.8M | -$10.6M | -$20.7M | -$14.3M | -$15.7M |
| Diluted EPS | -$4.56 | -$47.88 | -$9.18 | — | — |
| Operating cash flow | -$9.2M | -$8.6M | -$7.3M | -$15.2M | -$13.5M |
| Free cash flow | — | — | — | -$15.4M | -$13.5M |
| Total assets | $10.1M | $1.5M | $5.0M | $14.8M | $28.2M |
| Total liabilities | $1.8M | $1.7M | — | — | — |
| Stockholders' equity | $8.3M | -$211,885 | $3.2M | $13.0M | $26.5M |
| Cash and investments | $8.4M | $864,840 | $3.5M | $11.4M | $27.3M |
| Total debt | — | — | $9,811 | $356,886 | $493,790 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Aug 28, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Shareholder vote results
|
Jul 6, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 19, 2026 | May 18, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
All 1003 Oragenics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.